SCT 200

Drug Profile

SCT 200

Alternative Names: Recombinant full human Anti-EGFR Monoclonal Antibody - Sinocelltech; SCT200

Latest Information Update: 20 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sinocelltech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 01 Jan 2015 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT02211443)
  • 05 Aug 2014 Preclinical trials in Colorectal cancer in China (Parenteral)
  • 05 Aug 2014 Sinocelltech plans a phase I trial for Colorectal cancer (metastatic disease, second-line therapy or greater) in China (NCT02211443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top